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Abstract
Introduction. We present what is believed to be the first report of candidaemia caused by Cyberlindnera (Pichia) jadinii
(teleomorph of Candida utilis) in a patient with an aplastic anaemia.
Case presentation. The patient, a 21-year-old male, presented with hepatic cytolysis, cutaneous and pulmonary involvement,
and septic shock. Cyberlindnera jadinii was identified by aerobic blood culture and MS. The patient initially received multiple
and combined antifungal therapy, but continued to have persistent skin lesions and fever. He was successfully treated by
emergency haploidentical haematopoietic stem cell transplantation, combined with triple antifungal therapy and
supportive care.
Conclusion. Cyberlindnera jadinii, teleomorph of Candida utilis, which is not usually invasive, can lead to an opportunistic
invasive infection in unhealthy adult patients. For treatment of the invasive candida infection, it is necessary to combine
antifungal therapy and supportive care.
INTRODUCTION
Herein, we describe what is to the best of our knowledge the
first report of candidaemia caused by Cyberlindnera (Pichia)
jadinii (teleomorph of Candida utilis) in a patient with an
aplastic anaemia.
CASE REPORT
A 21-year-old male was admitted to the Centre Henri
Becquerel, Rouen, France, with asthenia, fever (39

C) and
icterus on July 15 2016. The patient reported having had
these symptoms for 2 weeks. Laboratory investigations indi-
cated pancytopenia (polynuclear neutrophils=0.6 g l 1; pla-
telets=6 g l 1; haemoglobin=12.5 g dl 1), acute cytolytic and
cholestatic hepatitis, and inflammatory syndrome. Viral
serology was negative. A myelogram revealed low bone mar-
row density and an absence of megakaryocytes. Medullary
biopsy confirmed medullary aplasia without fibrosis. The
karyotype was normal, and the patient was negative for par-
oxysmal nocturnal haemoglobinuria clones and Fanconi
disease. The patient, who worked in car body repair, had no
relevant medical history. In the absence of another aetiol-
ogy, a diagnosis of aplastic anaemia was established.
The same day, empirical antibiotherapy with piperacillin/
tazobactam (4 g/0.5 g every 8 h) i.v. was initiated. A physical
examination on July 21 2016 did not reveal the source of the
fever, and abdominal ultrasound and echocardiography
were normal. Six blood cultures were taken between July 14
and 25 2016. Two (July 23 and 25) were positive for yeast.
Cyberlindnera jadinii was identified from aerobic cultures
by MS. (The MICs are shown in Table 1).
Caspofungin therapy was initiated on July 26 2016 (70 mg
on day 1, followed by 50mg day 1). The same day, the
patient presented a diffuse, purplish maculo-papular erup-
tion. Cutaneous fungal infection was suspected, but the
cutaneous biopsy was inconclusive. On July 29 2016, the
patient displayed persistent fever despite the caspofungin
therapy, so caspofungin was replaced by intravenous (i.v.)
liposomal amphotericin B (3mg kg 1 day 1).
On August 1 2016, the patient still presented with a contin-
uous fever (40

C), and the cutaneous eruption was exten-
sive. Pulmonary computed tomography showed alveolar
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and nodular opacities with fuzzy contours evoking a fungal
infection. Due to the patient’s worsening condition and the
computed tomography results, combined therapy with cas-
pofungin (50 mg every day i.v.) and i.v. liposomal ampho-
tericin B (3 mg kg 1 every day) was decided. The patient
continued to be febrile until August 4 2016, so tazocillin was
replaced by imipenem (1000mg every 8 h i.v.) and trimeth-
oprim/sulfamethoxazole (2400 mg/480 mg every day) to
treat uncertain pulmonary pneumocystosis. A new cutane-
ous biopsy was performed and, after 9 days of culture,
Malassezia sp. was found. A non-pathogenic species was
suspected.
Bronchoscopy on August 8 2016 did not reveal mucosal
lesions. However, macrophages and amphotericin B-sensi-
tive Candida kefyr were found in the bronchoalveolar lavage
while the patient was receiving combined antifungal
therapy.
Because of persisting skin lesions and fever, on August 9
2016, a new cutaneous biopsy was performed, revealing an
inflammatory perivascular reaction of the dermis and a
remodelling of hypodermic fat with mononuclear mobili-
zation. The patient was transferred to an intensive care
unit on August 11 2016 for septic shock and probable
invasive candidaemia. While there, the patient received i.v.
noradrenaline for a few hours. The patient became hypo-
thermic, so external warming was performed. Because of
the patient’s prolonged neutropenia, vancomycin (2 g
day 1 i.v.) was introduced. Because his clinical condition
improved, vancomycin was stopped on August 25 2016.
The patient continued to have cockade-like skin lesions
and no evidence of viral aetiology, with negative PCR for
cytomegalovirus, parvovirus B19, Epstein-Barr virus and
herpes simplex virus.
The patient was transferred back to the Centre Henri Bec-
querel on August 15 2016. He continued to present night
fever, and the cutaneous eruption gradually improved.
Aspergillus galactomannan antigenaemia was consistently
negative. In agreement with the Cyberlindnera jadinii-
positive blood culture, positivity to b-D-glucan (146 pgml 1
; negative <60 pgml 1), assessed September 5 2016, con-
firmed a fungal infection.
To manage the aplastic anaemia, haematopoietic stem cell
transplantation (HSCT) was considered. While awaiting a
compatible donor, the patient received classical doses of
granulocyte-colony stimulating factor and erythropoietin to
treat the anaemia. The patient’s 24-year-old brother and
other related donors, however, were not HLA-identical.
Although the patient did not meet the criteria for HSCT in
aplastic anaemia (age <40 years and no HLA-identical
familial donor) [1], given the severity of the patient’s illness
and the absence of a related or unrelated HLA-identical
donor, haploidentical HSCT using bone marrow from the
patient’s brother was indicated. The patient was A negative
and his brother was O negative. Both the patient and his
brother were positive for Epstein-Barr virus, and the patient
was immunized for cytomegalovirus.
On September 9 2016, 6 days before peripheral stem cell
infusion, a non-myeloablative conditioning regimen and
prophylaxis for graft-versus-host disease (GVHD) were ini-
tiated (Fig. 1). Prior to the transplant, the patient was
clinically stable with only temporary (12 h) fever. Bone mar-
row transplantation was performed on September 15 2016.
No immediate toxicity of the conditioning regimen or graft
was found. On day 1, the patient remained febrile with a
temperature of 39

C. Thoracic computed tomography
revealed nodular opacities evoking a mucosal infection.
Voriconazole (4 mg/kg evey day i.v.) was added to the con-
tinued antifungal therapy with caspofungin and liposomal
amphotericin B. Bronchoscopy and bronchoalveolar lavage
were negative.
The patient became afebrile on day 8. Voriconazole was
stopped 48 h later because the patient tested negative for
aspergillus, and all antibiotics were progressively termi-
nated. Caspofungin was replaced by fluconazole (200 mg
every day i.v.) on day 22. Starting on day 19, the patient
received oral cyclosporine (2 mg/kg evry day i.v.) to prevent
GVHD, and on day 27, the patient received valganciclovir
due to cytomegalovirus reactivation.
The last platelet transfusion was performed on day 16 and
the last blood transfusion on day 17. On day 18, the patient
was no longer aplastic, and on day 26, platelets were >20 g
l 1. The patient did not display acute GVHD. The whole
blood chimerism was 100% 7months after the
transplantation.
One-year post-transplantation, the patient decided to stop
all treatments. In January 2018, the patient was in complete
remission without GVHD.
DISCUSSION
This report describes what is believed to be the first case of
Cyberlindnera (Pichia) jadinii (Candida utilis) candidaemia
in a patient with aplastic anaemia. Cyberlindnera jadinii is
reported to be the teleomorphic parental species for Can-
dida utilis, a non-pathogenic yeast used as a food additive
[2]. Candida utilis is reported to been opportunistic patho-
gen and has been isolated from a few superficial clinical
specimens taken from immunocompromised patients [3],
newborns [4] and elderly adults [5]. Only a few cases of
Table 1. Susceptibility data for Cyberlindnera jadinii
Drug MIC at 48 h
(mg l 1)
Susceptible (S)/intermediate
(I)/resistant (R)
Fluconazole 4 I
Voriconazole 0.032 S
Amphotericin B 0.047 S
Anidulafungin 0.002 S
Caspofungin 0.032 S
5-Fluorocytosine 0.008 S
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Candida utilis candidaemia have been described. The first
was in 1988 in a 5-year-old male haemophiliac with AIDS
and a central catheter [6]. We suspect that this yeast entered
the patient’s bloodstream after colonizing his digestive tract.
Indeed, the fungal infection did not come from the central
catheter. The patient had peripheral catheters up to the allo-
genic HSCT, which were changed every 48 h, and peripheral
catheter cultures were never positive for C. jadinii. In addi-
tion, the delay between the positivity of the blood cultures
for C. jadinii, and the clinical presentation, fever and cuta-
neous eruption, was concordant.
According to the treatment algorithm for aplastic anaemia [1],
patients <40 years of age without a matching donor should be
first treated with horse anti-thymocyte globulin and cyclo-
sporine. In addition, invasive fungal infections have been his-
torically considered a contraindication for allogeneic HSCT
[7, 8]. Nevertheless, allogeneic HSCT was performed because
of the patient’s persistent fungal infection and fever despite tri-
ple antifungal therapy. Furthermore, recent retrospective data
indicate that allogeneic HSCT is feasible in patients with inva-
sive fungal infections [7, 8].
This case highlights the importance of invasive candida infec-
tion and the possibility that Candida utilis, not usually inva-
sive, can lead to an opportunistic invasive disease even in
otherwise healthy adult patients. In such cases, early diagnosis
of the fungal invasion and adapted supportive care are
essential.
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Fig. 1. Non-myeloablative conditioning and prophylaxis for GVHD. The patient received non-myeloablative conditioning including cyclo-
phosphamide and fludarabine starting on day  6 and total body irradiation on day  1. Therapy for GVHD included granulocyte-colony
stimulating factor (G-CSF), mycophenolate mofetil (MMF) and cyclosporine.
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